Defunct Company
Total Trials
5
As Lead Sponsor
0
As Collaborator
Total Enrollment
206
NCT00516802
A Study to Assess the Safety and Pharmacokinetics of an Inhibitor of PARP in Combination With Dacarbazine
Phase: Phase 1
Role: Collaborator
Start: Jan 31, 2007
Completion: Jan 31, 2009
NCT00494442
Study to Assess the Efficacy and Safety of a PARP Inhibitor for the Treatment of BRCA-positive Advanced Ovarian Cancer
Phase: Phase 2
Start: Jun 11, 2007
Completion: Jul 20, 2017
NCT00494234
Study to Assess The Efficacy and Safety of a PARP Inhibitor For The Treatment of BRCA-positive Advanced Breast Cancer
Start: Jun 15, 2007
Completion: Dec 21, 2022
NCT00516438
Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Topotecan
Start: Jul 31, 2007
Completion: Nov 30, 2009
NCT00633269
Study Assessing Metabolism, Excretion and Pharmacokinetics of a Poly (ADP-Ribose) Polymerase (PARP) Inhibitor in Patients With Solid Metastatic Tumours
Start: Apr 30, 2008
Completion: Oct 31, 2008